academic article

• CTLA-4 blockade synergizes therapeutically with PARP-inhibition in BRCA1-deficient ovarian cancer..  Cancer immunology research.  :-. 2015
• The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model..  Gynecologic oncology.  133:584-590. 2014